Effects of oversulfated and fucosylated chondroitin sulfates on coagulation

Summary

We report the effects of a chemically oversulfated chondroitin sulfate and a naturally fucosylated chondroitin sulfate on the coagulation system. The former has been recently identified as a contaminant of heparin preparations and the latter has been proposed as an alternative anticoagulant. The mechanism of action of these polymers on coagulation is complex and target different components of the coagulation system. They have serpin-independent anticoagulant activity, which preponderates in plasma. They also have serpin-dependent anticoagulant activity but differ significantly in the target coagulation protease and preferential serpin. Their anticoagulant effects differ even more markedly when tested as inhibitors of coagulation proteases using plasma as a source of serpins. It is possible that the difference is due to the high availability of fucosylated chondroitin sulfate whereas over-sulfated chondroitin sulfate has strong unspecific binding to plasma protein and low availability for the binding to serpins. When tested using a venous thrombosis experimental model, oversulfated chondroitin sulfate is less potent as an antithrombotic agent than fucosylated chondroitin sulfate. These highly sulfated chondroitin sulfates activate factor XII in in vitro assays, based on kallikrein release. However, only fucosylated chondroitin sulfate induces hypotension when intravenously injected into rats. In conclusion, the complexity of the regulatory mechanisms involved in the action of highly sulfated polysaccharides in coagulation requires their analysis by a combination of in vitro and in vivo assays. Our results are relevant due to the urgent need for new anticoagulant drugs or alternative sources of heparin.

Keywords

Heparin - kallikrein system - antithrombotic drugs - sulfated polysaccharides

• References

• 1 Crafoord C, Jorpes E. Heparin as a prophylactic against thrombosis. J Am Med Assoc 1941; 116: 2831-2842.
• 2 Ryckelynck JP, Chouraqui D, Lobbedez T. Anticoagulation of the extracorporeal circuit in chronic hemodialysis. Nephrologie 1998; 19: 223-225.
• 3 Mourão PAS, Pereira MS. Searching for alternatives to heparin. Trends Cardiovasc Med 1999; 09: 225-232.
• 4 Mourão PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Design 2004; 10: 967-981.
• 5 Borris LC. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag 2008; 04: 855-862.
• 6 Henry BL, Desai UR. Recent research developments in the direct inhibition of coagulation proteinases--inhibitors of the initiation phase. Cardiovasc Hematol Agents Med Chem 2008; 06: 323-336.
• 7 Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008; 34: 39-57.
• 8 Kishimoto TK, Viswanathan K, Ganguly T. et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467.
• 9 Pereira MS, Melo FR, Mourão PAS. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans?. Glycobiology 2002; 12: 573-580.
• 10 Guerrini M, Beccati D, Shriver Z. et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675.
• 11 Vieira RP, Mulloy B, Mourão PAS. Structure of a fucose-branched chondroitin sulfate from sea cucumber: evidence for the presence of 3-O-sulfo-β-D-glucuronosyl residues. J Biol Chem 1991; 266: 13530-13536.
• 12 Mourão PAS, Pereira MS, Pavão MSG. et al. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm: sulfated fucose branches on the polysaccharide account for its high anticoagulant activity. J Biol Chem 1996; 271: 23973-23984.
• 13 Pacheco RG, Vicente CP, Zancan P, Mourão PAS. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coag Fibrin 2000; 11: 563-573.
• 14 Maruyama T, Toida T, Imanari T. et al. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res. 1998; 306: 35-43.
• 15 Melo FR, Pereira MS, Foguel D. et al. Antithrombin-mediated anticoagulant activity of sulfated polysaccharides: different mechanisms for heparin and sulfated galactans. J Biol Chem 2004; 279: 20824-20835.
• 16 Farndale RW, Buttle DJ, Barret AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986; 883: 173-177.
• 17 Fonseca RJ, Oliveira SN, Melo FR. et al. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities. Thromb Haemost 2008; 99: 539-545.
• 18 Melo FR, Mourão PAS. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Thromb Haemost 2008; 99: 531-538.
• 19 Wessler S, Reimer SM, Sheps MC. Biologic assay of thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14: 943-946.
• 20 Beeler D, Rosenberg R, Jordan R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-2913.
• 21 Olson ST, Shore JD. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement. J Biol Chem 1981; 256: 11065-11072.
• 22 Glauser BF, Pereira MS, Monteiro RQ, Mourão PAS. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Thromb Haemost 2008; 100: 420-428.
• 23 Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209.
• 24 Alban S, Lühn S. Prothrombin time for detection of contaminated heparins. N Engl J Med 2008; 359: 2732-2734.
• 25 Melo FR, Pereira MS, Monteiro RQ. et al. Sulfated galactan is a catalyst of anti-thrombin-mediated inactivation of alpha-thrombin. Biochim Biophys Acta 2008; 1780: 1047-1053.
• 26 Jeske WP, Walenga JM, Adiguzel C. et al. Structural and functional characterization of low molecular weight heparins: Impact on the development of guidelines for generic products at www.natfonline.org/ethrombosis 2009
• 27 Li B, Suwan J, Martin JG. et al. Oversulfated chondroitin sulfate interact with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol 2009; 78: 292-300.
• 28 Gozzo AJ, Nues VA, Carmona AK. et al. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation. Immunopharmacology 2002; 02: 1861-1865.
• 29 Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175: 3377-3385.
• 30 Fonseca RJC, Mourão PAS. Fucosylated chondroitin sulfate as a new antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
• 31 Beyer T, Diehl B, Randel G. et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 2008; 48: 13-19.
• 32 Tami C, Puig M, Reepmeyer JC. et al. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 2008; 29: 4808-4814.
• 33 Sitkowski J, Bednarek E, Bocian W. et al. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J Med Chem 2008; 51: 7663-7665.
• 34 Domanig R, Jöbstl W, Gruber S. et al. One-dimensional cellulose acetate plate electrophoresis-A feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin. J Pharm Biomed Anal 2009; 49: 151-155.